The prognosis for breast cancer patients is generally favorable with ER+/PR+ tumors, intermediate with either ER+/PR− or ER−/PR+ tumors, but a devastating outcome for triple negative breast cancer (TNBC, ER−/PR−/HER2−). Here, ERBB2 is linked to breast carcinoma.